PLX vs XLK
Protalix Biotherapeutics Inc (PLX) versus Technology Select Sector SPDR® Fund (XLK) — a side-by-side from cached financials, not a winner call.
Protalix Biotherapeutics Inc (PLX) is a biotechnology company listed on US.
Technology Select Sector SPDR® Fund (XLK) common stock listed on US.
Latest reported PLX revenue for 2026-06-30 was $53.6M. Net income was $22.1M. Revenue was up 59.0% from 2026-03-31 to 2026-06-30. PLX currently screens at market cap $122.6M and trailing P/E 30.8.
XLK does not have a complete income-statement cache yet.
PLX currently screens at market cap $122.6M and trailing P/E 30.8. XLK currently screens at market cap $0.
Not investment advice. Open the PLX and XLK stock pages for the full models.
Not investment advice.